CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Weesp, NL (2010 - 2016)
Hoofddorp, NL (2018 - 2022)

Company Filing History:

5 out of 67

Solvay Pharmaceuticals, B.v.

Abbvie Bahamas Limited

patents

5. 1 out of 5

Abbott Healthcare Products B.v.

patents

6. 1 out of 167

Abbvie Deutschland Gmbh and Co Kg

patents

where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11427598 - Spiro-cyclic amine derivatives as S1P modulators (2022-08-30),

2. 10807991 - Spiro-cyclic amine derivatives as S1P modulators (2020-10-20),

3. 10179791 - Spiro-cyclic amine derivatives as S1P modulators (2019-01-15),

4. 9951084 - Spiro-cyclic amine derivatives as S1P modulators (2018-04-24),

5. 9273017 - (Thio)morpholine derivatives as S1P modulators (2016-03-01),

6. 9045441 - (Thio)morpholine derivatives as S1P modulators (2015-06-02),

7. 8901108 - [object Object] (2014-12-02),

8. 8735388 - Heterocyclic compounds with affinity to muscarinic receptors (2014-05-27),

9. 8586606 - Heterocyclic compounds with affinity to muscarinic receptors (2013-11-19),

10. 8563723 - [object Object] (2013-10-22),

11. 8252930 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2012-08-28),

12. 8101619 - [object Object] (2012-01-24),

13. 8084473 - Heterocyclic compounds with affinity to muscarinic receptors (2011-12-27),

14. 7964728 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2011-06-21),

15. 7696383 - N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs (2010-04-13),

Title: Inventor Spotlight: Axel Stoit from Weesp, NL

Introduction:

Meet Axel Stoit, a prolific inventor hailing from Weesp, Netherlands. With an impressive portfolio of 15 patents under his belt, Axel Stoit is making waves in the world of pharmaceutical innovation.

Latest Patents:

One of Axel's latest groundbreaking patents is for Spiro-cyclic amine derivatives as S1P modulators. These compounds, with specific molecular structures, exhibit affinity to S1P receptors and show great potential in the treatment, alleviation, or prevention of diseases where these receptors are involved.

Career Highlights:

Axel Stoit has made significant contributions to the field of pharmaceuticals through his work at renowned companies such as Solvay Pharmaceuticals B.V. and Abbvie B.V. His expertise and innovative mindset have propelled him to the forefront of drug development, where his patents are paving the way for new therapeutic interventions.

Collaborations:

Throughout his career, Axel has collaborated with esteemed professionals in the industry, including Hein K A C Coolen and Cornelis G Kruse. Together, they have pushed the boundaries of pharmaceutical research and development, delivering novel solutions to complex medical challenges.

Conclusion:

In conclusion, Axel Stoit stands out as a male inventor whose ingenuity and dedication have led to groundbreaking innovations in the field of pharmaceuticals. With a keen eye for scientific discovery and a passion for making a difference, Axel continues to shape the future of healthcare through his pioneering patents and collaborative efforts.

This text is generated by artificial intelligence and may not be accurate.